ENDV Pengajuan SEC - Endonovo Therapeutics, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1528172

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Endonovo Therapeutics, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

February 2, 2024	15-12G	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 OMB Number: 3235-0167 Expires: July 31, 2024 Estimated average burden hours per response 1.50 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT O
January 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 29, 2023 ENDONOVO THERAP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 29, 2023 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55453 45-2552528 (State or other jurisdiction of incorporation) (Comm
January 3, 2024	EX-10.1	AMENDMENT TO AGREEMENT Exhibit 10.1 AMENDMENT TO AGREEMENT THIS AMENDMENT AGREEMENT, dated as of December 29, 2023 (this “Amendment”), by and between Evermed Medical Enterprise Ltd (the “EVERMED”) and Endonovo Therapeutics, Inc. (“ENDONOVO”), amends the Sales and Strategic Partnership Agreement (the “Agreement”) dated May 18, 2020. WTNESSETH: WHEREAS, the parties entered into the Agreement dated May 18, 2020 whereby EVE
December 29, 2023	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A-1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A-1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55453 E
December 29, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55453 ENDON
December 4, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 4, 2023 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55453 45-2552528 (State or other jurisdiction of incorporation) (Commi
December 4, 2023	EX-10.1	Asset Purchase Agreement Exhibit 10.1 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (the “Agreement”), is entered into and effective as of December 3, 2023 (the “Signing Date”) by and among SofPulse, Inc., a Delaware corporation (the “Buyer”), Endonovo Therapeutics, Inc., a Delaware corporation (“ENDV” and/or “Seller”). Buyer and Seller are referred to individually herein as a “Party” and collectively herein as t
November 15, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55453 CUSIP NUMBER NOTIFICATION OF LATE FILING 29272H 201 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ T
October 12, 2023	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 5, 2023 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55453 45-2552528 (State or other jurisdiction of incorporation) (Commis
October 12, 2023	EX-99.1	Taiwan License and translation Exhibit 99.1
August 25, 2023	PART II AND III	As filed with the Securities and Exchange Commission on August 25, 2023 PART II – INFORMATION REQUIRED IN OFFERING CIRCULAR As filed with the Securities and Exchange Commission on August 25, 2023 PART II – INFORMATION REQUIRED IN OFFERING CIRCULAR An Offering Statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”).
August 25, 2023	ADD EXHB	ADD EXHB Exhibit 11.1
August 21, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55453 ENDONOVO T
August 15, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55453 CUSIP NUMBER NOTIFICATION OF LATE FILING 29272H 201 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transi
June 14, 2023	ADD EXHB	SUBSCRIPTION AGREEMENT Exhibit 4.1 SUBSCRIPTION AGREEMENT THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBL
June 14, 2023	ADD EXHB	J.H. Darbie & Co. 48 Wall Street, Suite 1206 New York, NY 10005 Telephone: 212-269-7271 Fax: 212-269-7330 Exhibit 1.3 Endonovo Therapeutics, Inc. 6320 Canoga Avenue 15th Floor Woodland Hills, CA 91367 Re: Finder’s Fee Agreement Amendment Dear Alan Collier: We refer to the Finder’s Fee Agreement, dated March 7, 2022 by and between us. We agree that the 120-day term of the agreement shall commence on June 7, 2023 and that the Finder’s Fee Agreement shall be otherwise unchanged. If the foregoing is accep
June 14, 2023	ADD EXHB	ADD EXHB Exhibit 11.1
June 14, 2023	PART II AND III	As filed with the Securities and Exchange Commission on June 14, 2023 PART II – INFORMATION REQUIRED IN OFFERING CIRCULAR As filed with the Securities and Exchange Commission on June 14, 2023 PART II – INFORMATION REQUIRED IN OFFERING CIRCULAR An Offering Statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”).
June 14, 2023	ADD EXHB	J.H. Darbie & Co. 48 Wall Street, Suite 1206 New York, NY 10005 Telephone: 212-269-7271 Fax: 212-269-7330 Exhibit 1.2 Endonovo Therapeutics, Inc. 6320 Canoga Avenue 15th Floor Woodland Hills, CA 91367 Re: Finder’s Fee Agreement Dear Alan Collier: As you know, Endonovo Therapeutics, Inc. (the “Issuer”), has expressed an interest in obtaining private equity or debt capital for various purposes. This letter agreement (“Agreement”) sets forth the terms and conditions upon which J.H. Darbie & Co., Inc. (“D
May 22, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55453 ENDONOVO
May 16, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55453 CUSIP NUMBER NOTIFICATION OF LATE FILING 29272H 201 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Trans
April 17, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55453 ENDONOVO THERAPEU
March 31, 2023	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55453 CUSIP NUMBER NOTIFICATION OF LATE FILING 29272H 201 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tr
March 29, 2023	EX-10.1	Binding Letter of Intent between the Company and PEMF Holdings, LLC, dated March 28, 2023. Exhibit 10.1 PEMF HOLDINGS, LLC 2302 Harpers Crossing Langhorne, PA 19047 March 23, 2023 Alan Collier, CEO Endonovo Therapeutics, Inc. 6320 Canoga Avenue, 15th Floor Woodland Hills, CA 91367 Subject: Purchase of SofPulse, Inc. Dear Mr. Collier: This Letter of Intent (“LOI”) is a firm commitment to purchase all the common shares of stock of SofPulse, Inc. (the “Company”), a Delaware corporation and
March 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2023 ENDONOVO THERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2023 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55453 45-2552528 (State or other jurisdiction of incorporation) (Commiss
November 21, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55453 ENDON
November 14, 2022	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55453 CUSIP NUMBER NOTIFICATION OF LATE FILING 29272H 201 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ T
September 27, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 26, 2022 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55453 45-2552528 (State or other jurisdiction of incorporation) (Com
September 27, 2022	EX-10.1	Asset Purchase Agreement Exhibit 10.1 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (the ?Agreement?), is entered into and effective as of September 26, 2022 (the ?Signing Date?) by and among Endonovo Therapeutics, Inc., a Delaware corporation (the ?Buyer?), Western Star Concrete, LLC, a Texas limited liability company (?Western Star? and/or ?Seller?) and Gabriel Mark Salmons (?Owner,? and collectively with Selle
August 22, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022. ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55453 ENDONOVO T
August 15, 2022	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55453 CUSIP NUMBER NOTIFICATION OF LATE FILING 29272H 201 (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transi
May 19, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022. ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55453 ENDONOVO
May 16, 2022	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55453 CUSIP NUMBER NOTIFICATION OF LATE FILING 29272H 201 (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Trans
May 10, 2022	ADD EXHB	ADD EXHB ADD EXHB 5 ex11-1.htm Exhibit 11.1
May 10, 2022	ADD EXHB	SUBSCRIPTION AGREEMENT Exhibit 4.1 SUBSCRIPTION AGREEMENT THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBL
May 10, 2022	ADD EXHB	FRANK J. HARITON ● ATTORNEY - AT - LAW Exhibit 12.1 FRANK J. HARITON ● ATTORNEY - AT - LAW 1065 Dobbs Ferry Road ● White Plains ● New York 10607 ● (Tel) (914) 674-4373 ● (Fax) (914) 693-2963 ● (e-mail) [email protected] May 9, 2022 Board of Directors Endonovo Therapeutics, Inc. 6320 Canoga Avenue -15th Floor Woodland Hills, CA Ladies and Gentlemen: I have acted as company counsel to Endonovo Therapeutics, Inc., a Delaware corporation
May 10, 2022	ADD EXHB	J.H. Darbie & Co. 48 Wall Street, Suite 1206 New York, NY 10005 Telephone: 212-269-7271 Fax: 212-269-7330 Exhibit 1.2 Endonovo Therapeutics, Inc. 6320 Canoga Avenue 15th Floor Woodland Hills, CA 91367 Re: Finder’s Fee Agreement Dear Alan Collier: As you know, Endonovo Therapeutics, Inc. (the “Issuer”), has expressed an interest in obtaining private equity or debt capital for various purposes. This letter agreement (“Agreement”) sets forth the terms and conditions upon which J.H. Darbie & Co., Inc. (“D
May 10, 2022	PART II AND III	As filed with the Securities and Exchange Commission on February 11, 2022 PART II – INFORMATION REQUIRED IN OFFERING CIRCULAR PART II AND III 2 partiiandiii.htm As filed with the Securities and Exchange Commission on February 11, 2022 PART II – INFORMATION REQUIRED IN OFFERING CIRCULAR An Offering Statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”). Information contained in this Preliminary Offering Circular is subject to completion or ame
April 14, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55453 ENDONOVO THERAPEU
March 31, 2022	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55453 CUSIP NUMBER NOTIFICATION OF LATE FILING 29272H 201 (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Tr
February 11, 2022	PART II AND III	As filed with the Securities and Exchange Commission on February 11, 2022 PART II – INFORMATION REQUIRED IN OFFERING CIRCULAR As filed with the Securities and Exchange Commission on February 11, 2022 PART II – INFORMATION REQUIRED IN OFFERING CIRCULAR An Offering Statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”).
February 11, 2022	ADD EXHB	Broker-Dealer Agreement Exhibit 1.1 Broker-Dealer Agreement This agreement (together with exhibits and schedules, the ?Agreement?) is entered into by and between Endonovo Therapeutics, Inc. (?Client?), a Delaware Corporation, and Dalmore Group, LLC., a New York Limited Liability Company (?Dalmore?). Client and Dalmore agree to be bound by the terms of this Agreement, effective as of February 3, 2022 (the ?Effective Date?
February 11, 2022	EX1A-11 CONSENT	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 11.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the use in this Registration Statement on Form 1-A of our report dated April 13, 2021, relating to the consolidated financial statements of Endonovo Therapeutics, Inc., and Subsidiaries for the years ended December 31, 2020 and 2019 and to the reference of our Firm under the caption “Experts”. Our report rel
November 19, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021. ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55453 ENDON
November 15, 2021	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55453 CUSIP NUMBER NOTIFICATION OF LATE FILING 29272H 201 (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? T
August 23, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021. ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55453 ENDONOVO T
August 16, 2021	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-55453 CUSIP NUMBER 29272H 201 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: June 30, 2021 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report o
May 24, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55453 ENDON
May 17, 2021	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-55453 CUSIP NUMBER 29272H 201 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2021 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report
April 13, 2021	10-K	Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55453 ENDONOVO THE
March 31, 2021	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-55453 CUSIP NUMBER 29272H 201 (Check one): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2020 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Repo
November 19, 2020	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55453 E
November 16, 2020	NT 10-Q	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-55453 CUSIP NUMBER 29272H 201 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: September 30, 2020 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Rep
August 19, 2020	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55453 ENDONO
August 11, 2020	NT 10-Q	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-55453 CUSIP NUMBER 29272H 201 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: June 30, 2020 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report o
August 7, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2020 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55453 45-2552528 (State or other jurisdiction of incorporation) (Commiss
August 7, 2020	EX-99.1	August 6, 2020 Exhibit 99.1 August 6, 2020 Dear Alan, Please except my resignation as President effective immediately. My resignation is for personal reasons and not due to any disagreements with the Company or its policies. I wish you and the company the greatest success for all the investors and of course, for my personal investments as well. If I can be of service, please call on me. Michael Mann
July 16, 2020	424B3	Endonovo Therapeutics, Inc. 4,923,036 Shares Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-239384 Prospectus Endonovo Therapeutics, Inc. 4,923,036 Shares Common Stock This prospectus relates to the offer and resale of up to 4,923,036 shares of our common stock, par value $0.0001 per share, by the selling stockholder, and Cavalry Fund I LP., or “Cavalry”. Cavalry has agreed to purchase up to $10,000,000 in share value pursuant to the
July 13, 2020	CORRESP	- ON ENDONOVO THERAPEUTICS LETTERHEAD July 13, 2020 Division of Corporate Finance U.
July 10, 2020	S-1/A	- As filed with the Securities and Exchange Commission on July 10, 2020 Registration No.
June 23, 2020	S-1	Registration Statement - As filed with the Securities and Exchange Commission on June 23, 2020 Registration No.
June 23, 2020	EX-3.13	Certificate of Designation, Series D Preferred Stock. Filed herewith Exhibit 3.13
June 12, 2020	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55453 ENDON
June 2, 2020	POS AM	- As filed with the Securities and Exchange Commission on June 2, 2020 Registration No.
June 2, 2020	RW WD	- June 2, 2020 Securities and Exchange Commission 100 F Street, N.E. Form RW filled May 29, 2020 (the “RW”) with respect to Amendment Number 1 to Registration Statement on Form S-1 filed January 8, 2019 Registration No. 333- 229146 and ordered Effective February 11, 2019. Ladies and Gentlemen: The undersigned issuer hereby requests that the above captioned RW be withdrawn. The issuer is filing a Pos
May 29, 2020	RW	- May 29, 2020 Securities and Exchange Commission 100 F Street, N.E. Amendment Number 1 to Registration Statement on Form S-1 Filed January 8, 2019 Registration No. 333- 229146 (the “Registration Statement”) Ordered Effective February 11, 2019 Ladies and Gentlemen: Pursuant to Rule 477 under the Securities Act of 1933, as amended, the undersigned issuer hereby requests that the above captioned Regis
May 26, 2020	EX-10.1	Equity Line Purchase Agreement by and between the Company and Calvary Fund I, LP, dated as of May 18, 2020 EXHIBIT 10.1 EQUITY LINE PURCHASE AGREEMENT THIS EQUITY LINE PURCHASE AGREEMENT (the “Agreement”), is entered into as of May 18, 2020 (the “Execution Date”), by and between Endonovo Therapeutics, Inc., a Delaware corporation (the “Company”), and Cavalry Fund I LP, a Delaware limited partnership (the “Investor”). RECITALS WHEREAS, the parties desire that, upon the terms and subject to the condition
May 26, 2020	EX-10.2	Registration Rights Agreement by and between the Company and Calvary Fund I, LP, dated as of May 18, 2020 EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 18, 2020 (the “Execution Date”), is entered into by and between Endonovo Therapeutics, Inc., a Delaware corporation (the “Company”) and Cavalry Fund I LP, a Delaware limited partnership (the “Investor”). Capitalized terms used herein and not otherwise defined herein shall have the resp
May 26, 2020	EX-10.3	Form of Note Modification and Forbearance Agreement. Incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed May 26, 2020. EXHIBIT 10.3 NOTE MODIFICATION AND FOREBAREANCE AGREEMENT Note Modification and Forbearance Agreement, dated as of May 20, 2020, by and among Endonovo Therapeutics, Inc., a Delaware corporation, with an address of 6320 Canoga Avenue - 15th Floor, Woodland Hills, CA 91367 (“ENDV”) and the party set forth on the signature page hereto (the “Lender”); WHEREAS, the Lender is the Holder of convertible p
May 26, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2020 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55453 45-2552528 (State or other jurisdiction of incorporation) (Commissio
May 19, 2020	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 19, 2020 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55453 45-2552528 (State or other jurisdiction of incorporation) (Commissio
May 14, 2020	NT 10-Q	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-55453 CUSIP NUMBER 29272H 201 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2020 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report
May 4, 2020	10-K	Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55453 ENDONOVO THER
April 10, 2020	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 10, 2020 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55453 45-2552528 (State or other jurisdiction of incorporation) (Commiss
March 26, 2020	NT 10-K	EDNV / ENDONOVO THERAPEUTICS, INC. NT 10-K - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-55453 CUSIP NUMBER 29272H 201 (Check one): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Repo
March 2, 2020	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2020 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55453 45-2552528 (State or other jurisdiction of incorporation) (Commissi
March 2, 2020	EX-99.1	99.1 Presentation regarding SofPulse®. Exhibit 99.1
February 3, 2020	8-K	Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 29, 2020 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55453 45-2552528 (State or other jurisdiction of incorporation) (Commi
February 3, 2020	EX-3.1	Certificate of Amendment to Certificate of Designation of Series C Preferred Stock. Incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed with the Securities and Exchange Commission on February 3, 2020.
December 19, 2019	EX-3.1	Articles of Amendment – Reverse Stock Split. Incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed with the Securities and Exchange Commission December 19, 2019.
December 19, 2019	8-K	Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 11, 2019 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55453 45-2552528 (State or other jurisdiction of incorporation) (Comm
November 19, 2019	10-Q	EDNV / ENDONOVO THERAPEUTICS, INC. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55453 E
November 14, 2019	DEF 14A	EDNV / ENDONOVO THERAPEUTICS, INC. DEF 14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [X] Definitive Information Statement Endonovo Therapeutics, Inc. (N
November 14, 2019	DEF 14C	EDNV / ENDONOVO THERAPEUTICS, INC. DEF 14C - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [X] Definitive Information Statement Endonovo Therapeutics, Inc. (N
November 14, 2019	NT 10-Q	EDNV / ENDONOVO THERAPEUTICS, INC. NT 10-Q - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-55453 CUSIP NUMBER 29272H 201 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: September 30, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Rep
October 30, 2019	PRE 14C	EDNV / ENDONOVO THERAPEUTICS, INC. PRE 14C - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Statement Endonovo Therapeutics, Inc. (N
August 13, 2019	10-Q	EDNV / ENDONOVO THERAPEUTICS, INC. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55453 ENDONO
June 13, 2019	EX-99.1	Marketing Plan with sales projections
June 13, 2019	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 10, 2019 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55453 45-2552528 (State or other jurisdiction of incorporation) (Commissi
May 9, 2019	10-Q	EDNV / ENDONOVO THERAPEUTICS, INC. 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55453 ENDON
April 15, 2019	10-K	EDNV / ENDONOVO THERAPEUTICS, INC. (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55453 ENDONOVO THER
March 29, 2019	NT 10-K	EDNV / ENDONOVO THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-55453 CUSIP NUMBER 29272H 201 (Check one): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2018 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Repo
February 6, 2019	CORRESP	EDNV / ENDONOVO THERAPEUTICS, INC. Endonovo Therapeutics, Inc. February 6, 2019 Division of Corporate Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Endonovo Therapeutics, Inc. Registration Statement Form S-1 – Acceleration Request File No. 333-229146 Dear Sirs and/or Madam: This letter serves as our request, in accordance with Rule 461, for acceleration of the effectiveness of the abo
January 8, 2019	S-1/A	EDNV / ENDONOVO THERAPEUTICS, INC. S-1/A As filed with the Securities and Exchange Commission on January 7 , 2019 Registration No.
January 7, 2019	S-1	EDNV / ENDONOVO THERAPEUTICS, INC. S-1 As filed with the Securities and Exchange Commission on January 5, 2019 Registration No.
January 3, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 1, 2019 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55453 45-2552528 (State or other jurisdiction of incorporation) (Commis
January 3, 2019	EX-10.2	Registration Rights Agreement by and between the Company and Azure Capital, dated as of December 31, 2018. Incorporated by reference to like numbered exhibit to Current Report on Form 8-k filed with the Securities Exchange Commission on January 3, 2018. REGISTRATION RIGHTS AGREEMENT Registration Rights Agreement (the “Agreement”), dated as of December 31, 2018, by and between ENDONOVO THERAPEUTICS, INC.
January 3, 2019	EX-10.1	Investment Agreement by and between the Company and Azure Capital, dated as of December 31, 2018. Incorporated by reference to like numbered exhibit to Current Report on Form 8-k filed with the Securities Exchange Commission on January 3, 2018. INVESTMENT AGREEMENT INVESTMENT AGREEMENT (this “AGREEMENT”), dated as of December 31, 2018 by and between ENDONOVO THERAPEUTICS, INC.
December 7, 2018	EX-10.2	Secured $1,500,000 Convertible Promissory Note, dated as of November 30, 2018, issued by the Company and Eagle Equities, LLC. Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the Securities Exchange Commission on December 7, 2018. THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $1,500,000.
December 7, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 6, 2018 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55453 45-2552528 (State or other jurisdiction of incorporation) (Commi
December 7, 2018	EX-10.1	Exchange Agreement dated as of November 30, 2018, between the Company and Eagle Equities, LLC. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the Securities Exchange Commission on December 7, 2018. EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the “Agreement”) is as of November 30, 2018, by and among Endonovo Therapeutics, Inc.
November 13, 2018	10-Q	EDNV / ENDONOVO THERAPEUTICS, INC. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55453 E
September 24, 2018	EX-3.1	Articles of Amendment Authorizing additional Shares. Incorporated by reference to Exhibit 3.1 to Form 8-K filed with the Securities and Exchange Commission on September 18, 2018.
September 24, 2018	8-K	Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 18, 2018 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55453 45-2552528 (State or other jurisdiction of incorporation) (Com
August 28, 2018	DEF 14C	EDNV / ENDONOVO THERAPEUTICS, INC. DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [X] Definitive Information Statement Endonovo Therapeutics, Inc. (N
August 14, 2018	PRE 14C	EDNV / ENDONOVO THERAPEUTICS, INC. PRE 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Statement Endonovo Therapeutics, Inc. (N
August 14, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 12, 2018 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 333-176954 45-2552528 (State or other jurisdiction of incorporation) (Commi
August 14, 2018	EX-10.1	SALES AND MARKETING AGREEMENT SALES AND MARKETING AGREEMENT This Sales and Marketing Agreement (the “Agreement”) is entered into August 10, 2018 (“Effective Date”) by and between Endonovo Therapeutics, Inc.
August 13, 2018	10-Q	EDNV / ENDONOVO THERAPEUTICS, INC. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55453 ENDONO
May 18, 2018	10-Q	EDNV / ENDONOVO THERAPEUTICS, INC. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55453 ENDON
May 16, 2018	NT 10-Q	EDNV / ENDONOVO THERAPEUTICS, INC. NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-55453 CUSIP NUMBER 29272H 201 (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: March 31, 2018 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report
April 6, 2018	EX-4.1	Specimen Common Stock Certificate.
April 6, 2018	EX-3.3	EX-3.3
April 6, 2018	EX-3.4	EX-3.4
April 6, 2018	EX-10.6	Form of Note Payable to Eagle under the SPA- Filed Herewith
April 6, 2018	EX-3.2	EX-3.2
April 6, 2018	EX-10.8	Debt Purchase Agreement, dated April 7, 2017, by and among the Company, Eagle and Bellridge Capital, LLC – Filed Herewith
April 6, 2018	EX-3.6	Articles of Amendment – Increase Authorized Shares. Incorporated by reference to Exhibit 3.1 to Form 8-K filed with the Securities and Exchange Commission on January 24, 2014.
April 6, 2018	EX-3.7	Articles of Amendment – Reverse Stock Split. Incorporated by reference to Exhibit 3.7 to Form S-1 amendment filed with the Securities and Exchange Commission on October 6, 2016.
April 6, 2018	EX-10.3	Acquisition Agreement between the Company and We Heal Animals, Inc. (7)
April 6, 2018	EX-3.1	EX-3.1
April 6, 2018	EX-3.5	Articles of Amendment -Name Change. Incorporated by reference to Exhibit 3.1 to Form 8-K filed with the Securities and Exchange Commission on January 24, 2014.
April 6, 2018	EX-10.7	Form of Back End Note under the SPA- Filed Herewith
April 6, 2018	10-K	EDNV / ENDONOVO THERAPEUTICS, INC. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55453 ENDONOVO THER
April 3, 2018	NT 10-K	EDNV / ENDONOVO THERAPEUTICS, INC. NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-55453 CUSIP NUMBER 29272H 201 (Check one): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2017 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Repo
December 28, 2017	EX-10.2	The Note EXHIBIT 10.2 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE ?1933 ACT?) US $1,800
December 28, 2017	EX-10.3	Security Agreement EXHIBIT 10.3 SECURITY AGREEMENT This SECURITY AGREEMENT (the ?Agreement?), dated and effective as of the 21day of December, 2018, is made by Endonovo Therapeutics, Inc. (?Debtor?) having a notice address of 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA 91367 in favor of EAGLE EQUITIES, LLC, a Nevada limited liability company, with its address at 91 Shelton Ave, Suite 107, New Haven, CT 06511
December 28, 2017	EX-10.1	Security Purchase Agreement, dated December 21, 2017, between the Registrant and Eagle. EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of December 21, 2017, by and between Endonovo Therapeutics, Inc., a Delaware corporation, with headquarters located at 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA 91367, (the ?Company?), and EAGLE EQUITIES, LLC, a Nevada limited liability company, with its address at 91 Shelton Ave, Sui
December 28, 2017	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 21, 2017 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55453 45-2552528 (State or other jurisdiction of incorporation) (Comm
December 28, 2017	EX-10.4	The Warrant EXHIBIT 10.4 Except as permitted by Section 8 hereof, no transfer shall be made at any time unless the Company shall have been supplied with evidence reasonably satisfactory to it that such transfer is not in violation of the Securities Act of 1933, as amended (the ?Act?). ENDONOVO THERAPEUTICS, INC. WARRANT TO PURCHASE 1,800,000 SHARES OF COMMON STOCK AS HEREIN DESCRIBED Dated: as of December 21,
December 26, 2017	8-K	Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 22, 2017 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55453 45-2552528 (State or other jurisdiction of incorporation) (Comm
December 26, 2017	EX-10.4	Certificate of Designation Series C Preferred Stock. Incorporated by reference to Exhibit 10.4 to Current Report on Form 8-K filed with the Securities and Exchange Commission December 26, 2017. EXHIBIT 10.4 Endonovo Therapeutics, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C SECURED REDEEMABLE PREFERRED STOCK PURSUANT TO THE DELAWARE GENERAL CORPORATION LAW The undersigned hereby certifies that: 1. He is the CEO of Endonovo Therapeutics Inc., a Delaware corporation (the ?Corporation?). 2. The Corporation is authorized to issue 5,000,000 shares of pref
December 26, 2017	EX-10.3	Security Agreement, dated December 22, 2017, between the Registrant and Steven Gluckstern.
December 26, 2017	EX-10.5	Security Agreement, between the Registrant and the holders of the Series C Secured Redeemable Preferred Stock EXHIBIT 10.5 SECURITY AGREEMENT This SECURITY AGREEMENT (the ?Agreement?), dated and effective as of the 22 day of December, 2017, is made by Endonovo Therapeutics, Inc. (?Debtor?) having a notice address of 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA 91367 in favor of the persons listed on the Schedule of Secured Parties annexed hereto as amended from time to time acting through Frank J. H
December 26, 2017	EX-10.1	Settlement and Mutual Release, effective November 22, 2018, between the Company and Rio Grande Neurosciences, LLC. Incorporation by reference to Exhibit 10.1 to current report on Form 8-K filed with the Securities and Exchange Commission on December 26, 2017.
December 26, 2017	EX-10.2	Secured Promissory Note, dated December 22, 2017, payable to Steven Gluckstern.
November 9, 2017	10-Q/A	ENDV / Endonovo Therapeutics, Inc. 10-Q/A (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A-1 (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-554
November 7, 2017	10-Q	ENDV / Endonovo Therapeutics, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55453 E
August 10, 2017	10-Q	ENDV / Endonovo Therapeutics, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 333-176954 ENDON
May 12, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 333-176954 ENDO
April 17, 2017	EX-10.4	SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 7, 2017, by and between Endonovo Therapeutics, Inc.
April 17, 2017	EX-10.7	ENDONOVO THERAPEUTICS, INC. 10% CONVERTIBLE REDEEMABLE NOTE DUE APRIL 7, 2018 BACK END NOTE THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE "1933 ACT”) US $210,000.
April 17, 2017	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-183246 ENDONOVO THE
April 17, 2017	EX-10.8	DEBT PURCHASE AGREEMENT DEBT PURCHASE AGREEMENT This Debt Purchase Agreement (the ?Agreement?) made as of this 7th day of April 2017, by and between Eagle Equities, LLC (the ?Buyer or Investor?) and Bellridge Capital LLC (the ?Seller?).
April 17, 2017	EX-10.6	ENDONOVO THERAPEUTICS, INC. 10% CONVERTIBLE REDEEMABLE NOTE DUE APRIL 7, 2018 THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”) US $210,000.
April 3, 2017	NT 10-K	Endonovo Therapeutics 0-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 333-176954 CUSIP NUMBER 29272H 201 (Check one): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2016 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Rep
March 28, 2017	SC 13G	EDNV / ENDONOVO THERAPEUTICS, INC. / Tangiers Global, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. ) * Endonovo Therapeutics, Inc. (Name of issuer) Common Stock. $.0001 value per share (Title of class of securities) 29272H201 (CUSIP number) March 20, 2017 (Date of Event Which Requires filing of this Statement) Check the appropriate box to designate the ru
February 10, 2017	8-K	Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 7, 2017 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 333-176954 45-2552528 (State or other jurisdiction (Commission (IRS Employ
February 10, 2017	EX-3.1	Certificate of Designation Series B Preferred Stock. Incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed with the Securities and Exchange Commission February 10, 2017.
January 18, 2017	8-K	Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 17, 2017 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 333-176954 45-2552528 (State or other jurisdiction (Commission (IRS Employ
January 18, 2017	EX-3.1	EX-3.1
December 19, 2016	DEF 14C	Endonovo Therapeutics 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [X] Definitive Information Statement Endonovo Therapeutics, Inc. (Name
December 8, 2016	PRE 14C	Endonovo Therapeutics 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Statement Endonovo Therapeutics, Inc. (N
November 14, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 333-176954
October 19, 2016	424B3	ENDONOVO THERAPEUTICS, INC. 16,500,000 Shares of Common Stock PROSPECTUS ENDONOVO THERAPEUTICS, INC. 16,500,000 Shares of Common Stock This prospectus relates to the offer and resale of up to 16,676,057 shares of our common stock, par value $0.0001 per share, by the selling stockholder, Bellridge Capital, LP (?Bellridge?), and represent shares that Bellridge may acquire upon conversion of up to $1,000,000 principal amount of our 6% Senior Convertible Notes (
October 17, 2016	EX-4.1	EX-4.1
October 17, 2016	S-1/A	As filed with the Securities and Exchange Commission on October 17 , 2016 As filed with the Securities and Exchange Commission on October 17 , 2016 Registration No.
October 14, 2016	CORRESP	Endonovo Therapeutics ESP ENDONOVO THERAPEUTICS, INC. October 14, 2016 Division of Corporate Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Endonovo Therapeutics, Inc. Registration Statement Form S-1 – Acceleration Request File No. 333-213365 Dear Sirs and/or Madam: This letter serves as our request, in accordance with Rule 461, for acceleration of the effectiveness of the abo
October 6, 2016	EX-4.1	Specimen Common Stock Certificate. Incorporated by reference to like numbered Exhibit to Registration on Form S-1 amendment filed on June 10, 2016.
October 6, 2016	EX-10.6	AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT This Amended and Restated Securities Purchase Agreement (this ?Agreement?) is dated as of September 30, 2016, between Endonovo Therapeutics, Inc.
October 6, 2016	EX-21.1	IP Resources International, Inc. a Nevada Corporation owned 100% Exhibit 21.1 IP Resources International, Inc. a Nevada Corporation owned 100% We Heal Animals, Inc. a Texas Corporation owned 100% Aviva Companies Corp, a Nevada Corporation owned 100%
October 6, 2016	S-1/A	As filed with the Securities and Exchange Commission on October 6, 2016 As filed with the Securities and Exchange Commission on October 6, 2016 Registration No.
October 6, 2016	EX-3.7	Articles of Amendment – Reverse Stock Split. Incorporated by reference to Exhibit 3.7 to Form S-1 amendment filed with the Securities and Exchange Commission on October 6, 2016.
October 6, 2016	CORRESP	Endonovo Therapeutics ESP FRANK J. HARITON ATTORNEY - AT - LAW 1065 Dobbs Ferry Road White Plains New York 10607 (Tel) (914) 674-4373 (Fax) (914) 693-2963 (e-mail) [email protected] October 6, 2016 Ms. Suzanne Hayes, Assistant Director Office of Healthcare and Insurance Division of Corporation Finance Securities and Exchange Commission Washington, D.C. 20549 Re: Endonovo Therapeutics, Inc. Amendment Number 1 to Registrat
August 29, 2016	S-1	As filed with the Securities and Exchange Commission on August 29, 2016 As filed with the Securities and Exchange Commission on August 29, 2016 Registration No.
August 19, 2016	8-K	Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 19, 2016 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 333-176954 45-2552528 (State or other jurisdiction (Commission (IRS Employe
August 19, 2016	EX-99.1	Endonovo Therapeutics Receives Notice of Termination of Its Binding-Letter Agreement to Acquire Rio Grande Neurosciences Endonovo Therapeutics Receives Notice of Termination of Its Binding-Letter Agreement to Acquire Rio Grande Neurosciences Termination Results from Rio Grande?s Request to Renegotiate Terms of Acquisition LOS ANGELES, August 19, 2016 - Endonovo Therapeutics, Inc.
August 19, 2016	EX-99.1	Endonovo Therapeutics Receives Notice of Termination of Its Binding-Letter Agreement to Acquire Rio Grande Neurosciences Endonovo Therapeutics Receives Notice of Termination of Its Binding-Letter Agreement to Acquire Rio Grande Neurosciences Termination Results from Rio Grande?s Request to Renegotiate Terms of Acquisition LOS ANGELES, August 19, 2016 - Endonovo Therapeutics, Inc.
August 19, 2016	8-K	Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 19, 2016 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 333-176954 45-2552528 (State or other jurisdiction (Commission (IRS Employe
August 12, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO? SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 333-1
July 15, 2016	EX-10.3	SECURITIES PURCHASE AGREEMENT EXHIBIT 10.3 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July 8, 2016 by and between Endonovo Therapeutics, Inc., a Delaware corporation (the ?Company?) and Bellridge LP (the ?Purchaser). Capitalized terms used in this Agreement and not otherwise defined shall have the meanings ascribed to them in Article 1. WHEREAS, the parties desire that, u
July 15, 2016	EX-10.4	REGISTRATION RIGHTS AGREEMENT Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT, is by and between Endonovo Therapeutics, Inc., a Delaware corporation (the ?Company?), and Bellridge Capital LP(the ?Holder?), and is made pursuant to that certain Securities Purchase Agreement between the Company and the Holder, dated as of the date hereof (the ?Purchase Agreement?). WHEREAS, pursuant to the terms of a
July 15, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 12, 2016 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 333-176954 45-2552528 (State or other jurisdiction of incorporation) (Commiss
July 15, 2016	EX-10.2	6% Senior Convertible NOTE EXHIBIT 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS
July 15, 2016	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July 8, 2016, between Endonovo Therapeutics, Inc. a Delaware corporation (the ?Company?), and Bellridge Capital, LP including its successors and assigns, a ?Purchaser?). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an exemption from the registr
July 11, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 9, 2016 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 333-176954 45-2552528 (State or other jurisdiction of incorporation) (Commissi
July 11, 2016	EX-10.1	July 8, 2016 July 8, 2016 PRIVATE & CONFIDENTIAL RIO GRANDE NEUROSCIENCES, INC. (the “Company”) Chairman and CEO 6401 Richards Ave. Santa Fe, NM 87508 Attn.: Mr. Steven Gluckstern, Chairman & CEO Subject: Purchase of the Stock of Rio Grande Neurosciences, Inc. Dear Steven, This binding letter agreement (“LOI”), which has been approved by the Boards of Directors of each of the parties hereto and is subject only
July 11, 2016	EX-10.2	EX-10.2
June 13, 2016	EX-10.1	[Signature page follows immediately] CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the ?Agreement?) is made and entered into the 30th, day of November 2015 (the ?Effective Date?) Between: Regal Consulting, a limited liability company organized under the laws of the state of Delaware (the ?Consultant?), and Endonovo Therapeutics Inc.
June 13, 2016	EX-10.2	10% PER ANNUM, $250,000 CONVERTIBLE NOTE 10% PER ANNUM, $250,000 CONVERTIBLE NOTE FOR VALUE RECEIVED, Endonovo Therapeutics, Inc.
June 13, 2016	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 30, 2015 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 333-176954 45-2552528 (State or other jurisdiction of incorporation) (Com
May 27, 2016	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment #1 (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016. [ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment #1 (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number:
May 20, 2016	10-Q	Endonovo Therapeutics ENDV 10-Q 03/31/16 (Quarterly Report) ENDV 10-Q 03/31/16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 17, 2016	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 [ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333
May 16, 2016	NT 10-Q	Endonovo Therapeutics ENDV NT 10-Q 03/31/16 ENDV NT 10-Q 03/31/16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 5, 2016	EX-4.1	EXHIBIT 4.1 EXHIBIT 4.1
April 5, 2016	EX-3.7	EXHIBIT 3.7 EXHIBIT 3.7
April 5, 2016	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 [ ] TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-183246 ENDONOVO THE
March 31, 2016	NT 10-K	Endonovo Therapeutics ENDV NT 10-K 12/31/15 ENDV NT10-K 12/31/15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 11, 2016	POS AM	Endonovo Therapeutics ENDV POS AM 03/11/16 ENDV POS AM 03/11/16 As filed with the Securities and Exchange Commission on March 11, 2016 Registration No.
November 23, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015. [ ] TRANSITION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 333-176954
November 16, 2015	NT 10-Q	Endonovo Therapeutics ENDV NT 10-Q 09/30/15 ENDV NT 10-Q 09/30/15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
October 15, 2015	SC 13G	EDNV / ENDONOVO THERAPEUTICS, INC. / VIS VIRES GROUP, INC. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. )* ENDONOVO THERAPEUTICS, INC. (Name of issuer) Common Stock, $0.0001 value per share (Title of class of securities) 29272H201 (CUSIP number) October 15, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the
August 19, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015. [ ] TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 333-176954 ENDON
August 14, 2015	NT 10-Q	Endonovo Therapeutics ENDV NT 10-Q 06/30/15 ENDV NT10-Q 06/30/15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 15, 2015	8-A12G	Endonovo Therapeutics FOR REGISTRATION OF CERTAIN CLASSES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 45-2552528 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA 91367 (Address of principal executive offic
June 15, 2015	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014. ☐ TRA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014. ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 333-
June 15, 2015	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015. ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number:
May 19, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015. [ ] TRANSITION REP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 333-176954 ENDO
May 15, 2015	NT 10-Q	Endonovo Therapeutics ENDV NT 10-Q 03/31/15 ENDV NT10-Q 03/31/15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 1, 2015	RW	Endonovo Therapeutics ENDV RW 04/30/15 ENDV RW 04/30/15 April 30, 2015 Securities and Exchange Commission 100 F Street, N.
April 30, 2015	S-1/A	Endonovo Therapeutics ENDV S-1/A1 04/30/15 ENDV S-1/A1 04/30/15 As filed with the Securities and Exchange Commission on April 30, 2015 Registration No.
April 27, 2015	CORRESP	Endonovo Therapeutics ESP ENDV CORRESPONDENCE 04/28/15 Endonovo Therapeutics, Inc. April 27, 2014 Division of Corporate Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Endonovo Therapeutics, Inc. Registration Statement Form S-1 ? Acceleration Request File No. 333-202068 Dear Sirs and/or Madam: This letter serves as our request, in accordance with Rule 461, for acceleration of t
April 24, 2015	S-1/A	Endonovo Therapeutics ENDV S-1/A1 04/24/15 ENDV S-1/A1 04/24/15 As filed with the Securities and Exchange Commission on April 24, 2015 Registration No.
April 3, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 [ ] TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-183246 ENDONOVO THE
March 30, 2015	NT 10-K	Endonovo Therapeutics ENDV NT 10-K 12/31/14 ENDV NT 10-K 12/31/14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 13, 2015	S-1	EDNV / ENDONOVO THERAPEUTICS, INC. S-1 - Registration Statement - ENDV S-1 02/12/15 As filed with the Securities and Exchange Commission on February 13, 2015 Registration No.
January 21, 2015	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 20, 2015 ENDONOVO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 333-176954 45-2552528 (State or other jurisdiction of incorporation) (Comm
January 21, 2015	EX-10.2	REGISTRATION RIGHTS AGREEMENT EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement ("Agreement"), dated January 19, 2015, is made by and between ENDONOVO THERAPEUTICS, INC., a Delaware corporation ("Company"), and KODIAK CAPITAL GROUP, LLC a Delaware limited liability company (the "Investor"). RECITALS WHEREAS, upon the terms and subject to the conditions of the Equity Purchase Agreement ("Purchase Agr
January 21, 2015	EX-10.1	EQUITY PURCHASE AGREEMENT EXHIBIT 10.1 EQUITY PURCHASE AGREEMENT THIS EQUITY PURCHASE AGREEMENT entered into as of the 19th day of January, 2015 (this "AGREEMENT"), by and between KODIAK CAPITAL GROUP, LLC, a Delaware limited liability company ("INVESTOR"), and ENDONOVO THERAPEUTICS, INC., a Delaware corporation (the "COMPANY"). WHEREAS, the parties desire that, upon the terms and subject to the conditions contained herein
November 14, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014. [ ] TRANSITION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 333-176954
August 19, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014. [ ] TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 333-176954 ENDON
August 14, 2014	NT 10-Q	EDNV / ENDONOVO THERAPEUTICS, INC. NT 10-Q - - ENDO NT 10-Q 06/30/14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response………………………..2.50 SEC FILE NUMBER 333-176954 CUSIP NUMBER (Check one): [ ]Form 10-K [ ]Form 20-F [ ]Form 11-K [X ]Form 10-Q [ ]Form 10-D [ ]Form N-SAR [ ]Form N-CSR For Period Ended: June
May 15, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014. [ ] TRANSITION REP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 333-176954 ENDO
April 15, 2014	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 [ ] TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-183246 ENDONOVO THE
March 31, 2014	NT 10-K	- ENDO NT 10-K 12/31/13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response………………………..2.50 SEC FILE NUMBER 333-176954 CUSIP NUMBER (Check one): [X]Form 10-K [ ]Form 20-F [ ]Form 11-K [ ]Form 10-Q [ ]Form 10-D [ ]Form N-SAR [ ]Form N-CSR For Period Ended: Decem
January 24, 2014	EX-3.1	Articles of Amendment -Name Change. Incorporated by reference to Exhibit 3.1 to Form 8-K filed with the Securities and Exchange Commission on January 24, 2014. EXHIBIT 3.1
January 24, 2014	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders - HVPA 8-K 01/24/14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 22, 2014 HANOVER PORTFOLIO ACQUISITIONS, INC. (Exact name of registrant as specified in its charter) Delaware 333-176954 45-2552528 (State or other jurisdiction of incorporati
December 18, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013. [ ] TRANSITION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 333-176954
November 19, 2013	EX-10.1	Acquisition Agreement between the Company and We Heal Animals, Inc. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed November 19, 2013 EXHIBIT 10.1 ASSET PURCHASE AGREEMENT This ASSET PURCHASE AGREEMENT (this “Agreement”) is entered into as of November 16, 2013 (“Effective Date”), by and between Hanover Portfolio Acquisitions, Inc., with an office at 6320 Canoga Ave. 15th Floor, Woodland Hills, CA 91367 (“Purchaser”), WeHealAnimals, Inc., with an address at 1700 Rivercrest Dr. #1205 ,Sugar Land, TX 77478 (“Company”) and Dr. Donni
November 19, 2013	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 16, 2013 HANOVER PORTFOLIO ACQUISITIONS, INC. (Exact name of registrant as specified in its charter) Delaware 333-176954 45-2552528 (State or other jurisdiction of incorporat
November 14, 2013	NT 10-Q	- HVPA NT 10-Q 09/30/13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response………………………... 2.50 SEC FILE NUMBER 333-176954 CUSIP NUMBER (Check one): [ ]Form 10-K [ ]Form 20-F [ ]Form 11-K [X]Form 10-Q [ ]Form 10-D [ ]Form N-SAR [ ]Form N-CSR For Period Ended: Sep
October 11, 2013	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders - HVPA 8-K 10/11/13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 20, 2013 HANOVER PORTFOLIO ACQUISITIONS, INC. (Exact name of registrant as specified in its charter) Delaware 333-176954 45-2552528 (State or other jurisdiction of incorpora
October 11, 2013	EX-3.2	EX-3.2 EXHIBIT 3.2
October 11, 2013	EX-3.1	EXHIBIT 3.1 EXHIBIT 3.1
August 28, 2013	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Numb
August 19, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013. [ ] TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 333-176954 HANOV
August 14, 2013	NT 10-Q	- HVPA NT 10-Q 06/30/13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response………………………... 2.50 SEC FILE NUMBER 333-176954 CUSIP NUMBER (Check one): [ ]Form 10-K [ ]Form 20-F [ ]Form 11-K [X]Form 10-Q [ ]Form 10-D [ ]Form N-SAR [ ]Form N-CSR For Period Ended: Jun
June 21, 2013	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No.1) (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No.1) (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Numb
May 20, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013. [ ] TRANSITION REP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 333-176954 HANO
May 16, 2013	NT 10-Q	- HVPA NT 10-Q 03/31/13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response………………………... 2.50 SEC FILE NUMBER 333-176954 CUSIP NUMBER (Check one): [ ]Form 10-K [ ]Form 20-F [ ]Form 11-K [X]Form 10-Q [ ]Form 10-D [ ]Form N-SAR [ ]Form N-CSR For Period Ended: Mar
May 3, 2013	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 [ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333
April 16, 2013	EX-3.4	CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES AA SUPER VOTING PREFERRED STOCK OF HANOVER PORTFOLIO ACQUISITIONS, INC. Exhibit 3.4 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES AA SUPER VOTING PREFERRED STOCK OF HANOVER PORTFOLIO ACQUISITIONS, INC. Hanover Portfolio Acquisitions, Inc., a Delaware corporation (the ?Corporation?), DOES HEREBY CERTIFY: Pursuant to the authority expressly granted and vested in the Board of Directors of the Corporation by the provisions of the Corporation?s Certificate
April 16, 2013	EX-3.4	Certificate of Designation (Super AA Voting Preferred). Incorporated by reference to the Annual Report on Form 10-K for the year ended December 31, 2012 Exhibit 3.4 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES AA SUPER VOTING PREFERRED STOCK OF HANOVER PORTFOLIO ACQUISITIONS, INC. Hanover Portfolio Acquisitions, Inc., a Delaware corporation (the ?Corporation?), DOES HEREBY CERTIFY: Pursuant to the authority expressly granted and vested in the Board of Directors of the Corporation by the provisions of the Corporation?s Certificate
April 16, 2013	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 [ ] TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-183246 HANOVER PORT
April 16, 2013	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 [ ] TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-183246 HANOVER PORT
April 9, 2013	8-K/A	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events - HVPA 8-K/A 04/08/13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 2, 2013 HANOVER PORTFOLIO ACQUISITIONS, INC. (Exact name of registrant as specified in its charter) Delaware 333-176954 45-2552528 (State or other jurisdiction of incorporatio
April 9, 2013	EX-99.3	Hanover Completes Acquisition of Israeli Technology Incubator EXHIBIT 99.3 Hanover Completes Acquisition of Israeli Technology Incubator LOS ANGELES, CA- (Marketwire - XXXXX, 2013) - Hanover Portfolio Acquisitions (OTCQB: HVPA), an intellectual property investment and monetization firm, announced today it has completed the acquisition of Israeli technology incubator, The Aviva Companies Corporation (“Aviva”). Aviva is a Texas-based incubator focused on the t
April 8, 2013	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events - HVPA 8-K 04/08/13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 2, 2013 HANOVER PORTFOLIO ACQUISITIONS, INC. (Exact name of registrant as specified in its charter) Delaware 333-176954 45-2552528 (State or other jurisdiction of incorporation)
April 8, 2013	EX-99.3	Hanover Completes Acquisition of Israeli Technology Incubator EXHIBIT 99.3 Hanover Completes Acquisition of Israeli Technology Incubator LOS ANGELES, CA- (Marketwire - XXXXX, 2013) - Hanover Portfolio Acquisitions (OTCQB: HVPA), an intellectual property investment and monetization firm, announced today it has completed the acquisition of Israeli technology incubator, The Aviva Companies Corporation (“Aviva”). Aviva is a Texas-based incubator focused on the t
April 1, 2013	NT 10-K	- HPAI NT 10-K 12/31/12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response………………………... 2.50 SEC FILE NUMBER 333-176954 CUSIP NUMBER (Check one): [X]Form 10-K [ ]Form 20-F [ ]Form 11-K [ ]Form 10-Q [ ]Form 10-D [ ]Form N-SAR [ ]Form N-CSR For Period Ended: Dec
November 29, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012. [ ] TRANSITION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 333-176954
November 21, 2012	NT 10-Q/A	- HPA NT 10-Q 09/30/12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response……………………... 2.50 SEC FILE NUMBER 333-176954 CUSIP NUMBER (Check one): [ ]Form 10-K [ ]Form 20-F [ ]Form 11-K [X]Form 10-Q [ ]Form 10-D [ ]Form N-SAR [ ]Form N-CSR For Period Ended: Sept
November 15, 2012	NT 10-Q	- HANOVER NT10-Q 09/30/12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response………………………... 2.50 SEC FILE NUMBER 333-176954 CUSIP NUMBER (Check one): [ ]Form 10-K [ ]Form 20-F [ ]Form 11-K [X]Form 10-Q [ ]Form 10-D [ ]Form N-SAR [ ]Form N-CSR For Period Ended: Sep
August 20, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012. [ ] TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012. [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 333-176954 HANOV
August 14, 2012	NT 10-Q	- HANOVER NT 10-Q 06/30/12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2012 Estimated average burden hours per response………………………... 2.50 SEC FILE NUMBER 333-176954 CUSIP NUMBER (Check one): [ ]Form 10-K [ ]Form 20-F [ ]Form 11-K [X]Form 10-Q [ ]Form 10-D [ ]Form N-SAR [ ]Form N-CSR For Period Ended: Jun
May 21, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) [X] QUARTERLY REPORT PURSUANT SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012. [ ] TRANSITION REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) [X] QUARTERLY REPORT PURSUANT SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012. [ ] TRANSITION REPORT PURSUANT SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 333-176954 HANOVER PORTFO
May 15, 2012	NT 10-Q	- HANOVER NT 10-Q 03/31/12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 333-176954 FORM 12b-25 CUSIP NUMBER NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ]Form 20-F [ ]Form 11-K [ X]Form 10-Q [ ]Form N-SAR [ ]Form N-CSR For Period Ended: March 31, 2012 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K Transition Report on Form 10-Q Transition R
April 13, 2012	10-K	UNITED STATES 10-K 1 hanover10k123111apg2.htm HANOVER 10-K 12/31/11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 Commission File Number: 333-176954 HANOVER PORTFOLIO ACQUISITIONS, INC. (Exact name of registrant as specified in its charter) Delaware
March 30, 2012	NT 10-K	- HPA NT 10-K 12/31/11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 333-176954 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [X] Form 10-K [ ]Form 20-F [ ]Form 11-K [ ]Form 10-Q [ ]Form N-SAR [ ]Form N-CSR For Period Ended: December 31, 2011 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K Transition Report on Form 10-Q Transit

ENDV / Endonovo Therapeutics, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)